98%
921
2 minutes
20
We aimed to evaluate the retina and the choroid in children with juvenile idiopathic arthritis (JIA) employing optical coherence tomography (OCT). This cross-sectional study, carried out between June 2017-December 2019, included JIA patients with (JIAU; n = 28) and without (JIAN; n = 65) uveitis and age-matched healthy controls (HC) (n = 102). Laboratory and demographic information of the children were obtained from hospital records. Activity of the disease was evaluated by the Juvenile Arthritis Disease Activity Score-71 (JADAS-71). Choroidal scans were obtained with spectral domain-OCT in enhanced-depth imaging (EDI)-OCT mode to assess choroidal thickness (ChT) at five locations (under the fovea, at 750 and 1500 μm nasal and temporal sections), luminal area (LA), stromal area (SA), total subfoveal choroidal area (TCA) and CVI (choroidal vascularity index). Central foveal thickness (CFT) and 1-mm diameter foveal thickness (FT) were calculated automatically through macular volume scan analysis. The choroid was significantly thicker in JIAU and JIAN patients than in HC at the subfoveal and at the 750N, 750T, 1500T points (p < 0.001, p = 0.009, p < 0.001, and p < 0.001, respectively). The CVI was lower in JIAU patients than in JIAN patients and HC (p = 0.02). Conversely, CFT was greater in JIAU patients as compared to the JIAN patients and HC (p = 0.02). Changes in chorioretinal OCT parameters in the absence of uveitis in JIA patients may reflect subclinical choroidal inflammation in these patients. Ophthalmologic examination, including choroidal imaging in a larger cohort, may clarify this aspect.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00296-021-05023-x | DOI Listing |
Front Immunol
September 2025
Department of Pediatrics, Taichung Veterans General Hospital, Taichung, Taiwan.
Introduction: Human papillomavirus (HPV) infection has been implicated in autoimmune processes, yet concerns remain about the potential autoimmune risks of HPV vaccination. Juvenile idiopathic arthritis (JIA) is a chronic autoimmune condition that typically manifests in childhood. The relationship between HPV vaccination and the development of JIA remains uncertain.
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Department of Ophthalmology, Inonu University Faculty of Medicine, Malatya, Turkey.
Uveitis is an inflammation of the anatomical layer, which consists of the iris, ciliary body and choroid. Pediatric uveitis is rare, but tends to be more severe and chronic than in adults. This study aims to evaluate the etiology, clinical features, treatment and complications in pediatric uveitis.
View Article and Find Full Text PDFNepal J Epidemiol
September 2025
Sir Seewoosagur Ramgoolam Medical College, Belle Rive, Mauritius.
Background: Arthritis affects millions of people worldwide; however, its mismanagement remains a growing global challenge, resulting in reduced quality of life (QoL) and disability. Digital health (DH), including smartphones, could be the key to solving this problem. Specific evidence-based reviews on the use of DH in this context are lacking.
View Article and Find Full Text PDFJ Christ Nurs
September 2025
Christy Jeffcoat, DNP, RN, EBP-C , is an assistant professor at University of South Carolina College of Nursing. Her areas of interest include women's health, maternal mental health, juvenile idiopathic arthritis, lateral violence in nursing, and various aspects of evidence-based practice.
Lancet Rheumatol
September 2025
Bristol Royal Hospital for Children and Translational Health Sciences, Bristol, UK. Electronic address:
Background: Baricitinib has previously been shown to improve clinical response in patients with juvenile idiopathic arthritis (JIA) in the JUVE-BASIS trial. In this post-hoc analysis we aimed to identify whether pharmacodynamic changes in serum biomarkers in response to baricitinib treatment could help reaffirm the clinical utility of baricitinib in patients with JIA.
Methods: JUVE-BASIS was a randomised, double-blind, placebo-controlled, withdrawal, efficacy, safety, phase 3 trial, done in 75 centres in 20 countries.